Stock KDEV KAROLINSKA DEVELOPMENT AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Karolinska Development AB

Equities

KDEV

SE0002190926

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:47 2024-06-07 am EDT 		5-day change 1st Jan Change
1.502 SEK -1.70% Intraday chart for Karolinska Development AB -1.18% -11.54%
May. 28 Karolinska Development Targets 10% Stake in Boost Pharma MT
May. 28 Boost Pharma Aps announced that it expects to receive funding from Industrifonden, Karolinska Development AB CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Karolinska Development Targets 10% Stake in Boost Pharma
MT
Karolinska Development invests in BOOST Pharma, expanding its portfolio
GL
Boost Pharma Aps announced that it expects to receive funding from Industrifonden, Karolinska Development AB
CI
Karolinska Development : Annual General Meeting 2024
PU
Karolinska Development’s Annual General Meeting 2024
GL
Karolinska Development AB Appoints Hans Wigzell as Director and as Chairman
CI
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
GL
Interim Report - January-March 2024
GL
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Notice of Annual General Meeting in Karolinska Development AB (publ)
GL
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election
CI
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
PU
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
GL
Karolinska Development Annual Report 2023 published
GL
Karolinska Development Annual Report 2023 published
AQ
Karolinska Development : portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
PU
Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million
GL
Karolinska Development : portfolio company Biosergen publishes prospectus due to rights issue of units
PU
Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units
GL
Karolinska Development : portfolio company Umecrine Cognition presents preclinical Parkinson's data on golexanolone at AD/PD
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KDEV Stock
  4. News Karolinska Development AB